Any reduction in viral load has immunologic benefits for people with HIV who have triple-class treatment failure

Michael Carter
Published: 08 January 2013

HIV therapy that achieves even modest reductions in viral load can have profound immunological benefits for people with triple-class treatment failure, European investigators report in the online edition of the Journal of Infectious Diseases.

“There is close to a linear inverse relationship between log viral load and CD4 count,” write the authors. “The…relationship between log viral load and CD4 count indicates that there are likely CD4 count benefits of lowering viral load even by modest amounts that do not lead to undetectable viral load levels.” They believe their findings are especially important “for patients with low CD4 cell counts and few drug options.”

The aim of antiretroviral therapy is an undetectable viral load. Ongoing HIV replication during treatment can lead to the emergence of drug resistance, limiting future treatment options and possibly leading to a poorer prognosis.

There have been considerable improvements in HIV therapy in recent years, and a number of new classes of antiretrovirals have been developed. Nevertheless, treatment remains based on the three main classes of anti-HIV drugs: nucleoside reverse transcriptase inhibitors (NRTIs); non-nucleoside reverse transcriptase inhibitors (NNRTIs); and ritonavir-boosted protease inhibitors (PI/r).

A small, but growing, number of people have experienced the failure of all three of these drug classes. Even with new therapies, their treatment is challenging. Rather than suppressing viral load, the object of treatment for people in this situation is often supporting CD4 cell count to reduce the risk of serious HIV-related illness. Understanding the factors associated with immune status after triple-class failure is therefore important.

As a result, investigators from the European COHERE study examined the records of 2424 people who had experienced triple-class failure since 1998.

Most of the patients (67%) were men and their median age was 40 years. The patients had been taking antiretroviral therapy for a median of four years before triple-class failure was diagnosed. Median viral load at this time was 4 log10 copies/ml, whereas median CD4 cell count was 270 cells/mm3.

The investigators’ initial analysis showed a strong linear association between CD4 cell count and viral load after treatment failure. CD4 cell count was 48 cells/mm3 lower per 1 log10 increase in viral load.

Only a small minority of people were treated with newer classes of antiretrovirals such as fusion inhibitors (7%), integrase inhibitors (9%) and CCR5 inhibitors (1%).

The investigators modelled changes in CD4 cell count two years after the emergence of triple-class failure. The model assumed that patients had a CD4 cell count of 300 cells/mm3 at this point.

Their calculations showed that people with a viral load of 2 log10 copies/ml would have a CD4 cell count of 386 cells/mm3 at the two-year time point. CD4 cell count fell steadily with each log10 increase in viral load, meaning that people with a 6 log10 viral load would have a CD4 cell count of just 213 cells/mm3.

“We have shown that current virus concentration in plasma is the single most important predictor of the current CD4 cell count attained among 2424 people who started ART since 1998 and then experienced triple-class failure,” comment the authors.

They believe their findings have important implications for the care of people with limited treatment options. “Any degree of viral suppression is likely to bring benefits in terms of CD4 count and hence risk of clinical disease,” the investigators comment. “While in those with high CD4 count it may be possible to wait until new active drugs are available, for those with low CD4 count it is important to use the regimen most likely to achieve maximal viral suppression. We found that the current viral load is closely linked to the CD4 count, suggesting a rapid benefit of viral load suppression, so in an individual who is not fully adherent, any increase in adherence is likely to provide immediate benefits in terms of reduced risk of clinical disease.”

Reference

Ledergerber B et al. Predictors of CD4 cell counts of HIV-1-infected persons after virologic failure of all three original antiretroviral drug classes. J Infect Dis, online edition, 2013.